ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2015 Jun 10

PMID 26058078

Citations 76

Authors

Liem T Nguyen

Maria S Tretiakova

Mark R Silvis

Jared Lucas

Olga Klezovitch

Ilsa Coleman

Hamid Bolouri

Vassily I Kutyavin

Colm Morrissey

Lawrence D True

Peter S Nelson

Valeri Vasioukhin

Affiliations

Soon will be listed here.

Abstract

The significance of ERG in human prostate cancer is unclear because mouse prostate is resistant to ERG-mediated transformation. We determined that ERG activates the transcriptional program regulated by YAP1 of the Hippo signaling pathway and found that prostate-specific activation of either ERG or YAP1 in mice induces similar transcriptional changes and results in age-related prostate tumors. ERG binds to chromatin regions occupied by TEAD/YAP1 and transactivates Hippo target genes. In addition, in human luminal-type prostate cancer cells, ERG binds to the promoter of YAP1 and is necessary for YAP1 expression. These results provide direct genetic evidence of a causal role for ERG in prostate cancer and reveal a connection between ERG and the Hippo signaling pathway.

Citing Articles

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.

AR and YAP crosstalk: impacts on therapeutic strategies in prostate cancer.

Zheng G, Yan Z, Zou J, Zou X, Chai K, Zhang G Front Oncol. 2025; 15:1520808.

PMID: 39963114 PMC: 11830605. DOI: 10.3389/fonc.2025.1520808.

Doublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer.

Jiang D, Li J, Ma H, Yan B, Lei H Int J Med Sci. 2025; 22(2):460-472.

PMID: 39781521 PMC: 11704687. DOI: 10.7150/ijms.99062.

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.

Olatunde D, De Benedetti A Cancers (Basel). 2024; 16(16).

PMID: 39199688 PMC: 11352418. DOI: 10.3390/cancers16162918.

Mitogen signaling strength and duration can control cell cycle decisions.

Nussinov R, Zhang W, Liu Y, Jang H Sci Adv. 2024; 10(27):eadm9211.

PMID: 38968359 PMC: 11809619. DOI: 10.1126/sciadv.adm9211.

References

Yu J, Yu J, Mani R, Cao Q, Brenner C, Cao X . An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17(5):443-54. PMC: 2874722. DOI: 10.1016/j.ccr.2010.03.018. View

Sharma P, Schreiber-Agus N . Mouse models of prostate cancer. Oncogene. 1999; 18(38):5349-55. DOI: 10.1038/sj.onc.1203037. View

Klezovitch O, Chevillet J, Mirosevich J, Roberts R, Matusik R, Vasioukhin V . Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004; 6(2):185-95. DOI: 10.1016/j.ccr.2004.07.008. View

Camargo F, Gokhale S, Johnnidis J, Fu D, Bell G, Jaenisch R . YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007; 17(23):2054-60. DOI: 10.1016/j.cub.2007.10.039. View

Wang J, Cai Y, Shao L, Siddiqui J, Palanisamy N, Li R . Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res. 2010; 71(4):1325-33. PMC: 3041849. DOI: 10.1158/0008-5472.CAN-10-2210. View

Carver B, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C . ETS rearrangements and prostate cancer initiation. Nature. 2009; 457(7231):E1. PMC: 2967456. DOI: 10.1038/nature07738. View

Wang J, Cai Y, Yu W, Ren C, Spencer D, Ittmann M . Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008; 68(20):8516-24. PMC: 2597580. DOI: 10.1158/0008-5472.CAN-08-1147. View

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

Nava Rodrigues D, Hazell S, Miranda S, Crespo M, Fisher C, de Bono J . Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology. 2014; 66(6):898-901. DOI: 10.1111/his.12493. View

10.

Casey O, Fang L, Hynes P, Abou-Kheir W, Martin P, Tillman H . TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One. 2012; 7(7):e41668. PMC: 3408501. DOI: 10.1371/journal.pone.0041668. View

11.

Qin J, Wu S, Creighton C, Dai F, Xie X, Cheng C . COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature. 2012; 493(7431):236-40. PMC: 4022346. DOI: 10.1038/nature11674. View

12.

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

13.

Gupta S, Iljin K, Sara H, Mpindi J, Mirtti T, Vainio P . FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010; 70(17):6735-45. DOI: 10.1158/0008-5472.CAN-10-0244. View

14.

King J, Xu J, Wongvipat J, Hieronymus H, Carver B, Leung D . Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41(5):524-6. PMC: 2898503. DOI: 10.1038/ng.371. View

15.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

16.

Martin P, Liu Y, Pierce R, Abou-Kheir W, Casey O, Seng V . Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol. 2011; 179(1):422-35. PMC: 3123810. DOI: 10.1016/j.ajpath.2011.03.035. View

17.

Lamar J, Stern P, Liu H, Schindler J, Jiang Z, Hynes R . The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012; 109(37):E2441-50. PMC: 3443162. DOI: 10.1073/pnas.1212021109. View

18.

Wu X, Wu J, Huang J, Powell W, Zhang J, Matusik R . Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001; 101(1-2):61-9. DOI: 10.1016/s0925-4773(00)00551-7. View

19.

Liang G, Lin J, Wei V, Yoo C, Cheng J, Nguyen C . Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A. 2004; 101(19):7357-62. PMC: 409923. DOI: 10.1073/pnas.0401866101. View

20.

Zhao B, Ye X, Yu J, Li L, Li W, Li S . TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22(14):1962-71. PMC: 2492741. DOI: 10.1101/gad.1664408. View